fda warning letters compounded semaglutide tirzepatide september 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA Issues 30 Warning Letters

In-person medical weight loss programs often include nutritional counseling, behavioral support, and more frequent provider interaction than typical telehealth platforms offer

In this article, we provide five GLP-1 boosting smoothie recipes fit for the summer months and beyond

She is not diabetic, but, you know how THAT goes

In some embodiments, the otic formulation or composition comprises about 2% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof

It is not yet proven by dedicated RCTs in this specific population

Impairment of methionine circulation, abnormal trans-sulfur metabolism (142, 158), and alterations in DNA methylation (162) have been shown to be associated with the development of ASD (155)